{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:27:00Z","timestamp":1792895220953,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2022-CF-EMCR-004-25314"],"award-info":[{"award-number":["2022-CF-EMCR-004-25314"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejpb.2024.114453","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T15:40:37Z","timestamp":1723304437000},"page":"114453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Contrasting the pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic"],"prefix":"10.1016","volume":"203","author":[{"given":"Tahlia R.","family":"Meola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia S.","family":"Elz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive A.","family":"Prestidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wignall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114453_b0005","article-title":"Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review","volume":"30","author":"Kumar","year":"2013","journal-title":"Critical Reviews\u2122 in Therapeutic Drug Carrier Systems"},{"key":"10.1016\/j.ejpb.2024.114453_b0010","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.xphs.2022.12.008","article-title":"Biorelevant dissolution method considerations for the appropriate evaluation of amorphous solid dispersions: are two stages necessary?","volume":"112","author":"Wang","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114453_b0015","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.apsb.2021.05.014","article-title":"Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies","volume":"11","author":"Bhujbal","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2024.114453_b0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.addr.2007.10.010","article-title":"Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies","volume":"60","author":"Pouton","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114453_b0025","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/molecules28052212","article-title":"Supersaturation and precipitation applicated in drug delivery systems: Development strategies and evaluation approaches","volume":"28","author":"Gan","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2024.114453_b0030","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/17425247.2023.2223937","article-title":"The impact of common pharmaceutical excipients on the gut microbiota","volume":"20","author":"Subramaniam","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114453_b0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/17425247.2023.2233900","article-title":"Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery","volume":"20","author":"Kamath","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114453_b0040","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/ecco-jcc\/jjaa254","article-title":"Food additive emulsifiers and their impact on gut microbiome, permeability, and inflammation: Mechanistic insights in inflammatory bowel disease","volume":"15","author":"Bancil","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.ejpb.2024.114453_b0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/j.gastro.2021.11.006","article-title":"Randomized controlled-feeding study of dietary emulsifier carboxymethylcellulose reveals detrimental impacts on the gut microbiota and metabolome","volume":"162","author":"Chassaing","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2024.114453_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature14232","article-title":"Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome","volume":"519","author":"Chassaing","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2024.114453_b0055","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/gutjnl-2016-313099","article-title":"Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation","volume":"66","author":"Chassaing","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ejpb.2024.114453_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40168-020-00996-6","article-title":"Direct impact of commonly used dietary emulsifiers on human gut microbiota","volume":"9","author":"Naimi","year":"2021","journal-title":"Microbiome"},{"key":"10.1016\/j.ejpb.2024.114453_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108229","article-title":"Dietary emulsifiers directly impact adherent-invasive E. coli gene expression to drive chronic intestinal inflammation","volume":"33","author":"Viennois","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejpb.2024.114453_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/0008-5472.CAN-16-1359","article-title":"Dietary emulsifier\u2013induced low-grade inflammation promotes colon carcinogenesis","volume":"77","author":"Viennois","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114453_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123614","article-title":"Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats","volume":"648","author":"Subramaniam","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114453_b0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4081\/cp.2017.987","article-title":"Gut microbiota's effect on mental health: The gut-brain axis","volume":"7","author":"Clapp","year":"2017","journal-title":"Clin Pract"},{"key":"10.1016\/j.ejpb.2024.114453_b0085","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-pharmtox-010919-023628","article-title":"Microbiota-gut-brain axis: New therapeutic opportunities","volume":"60","author":"Long-Smith","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejpb.2024.114453_b0090","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00058-23","article-title":"Longitudinal gut microbiota dysbiosis underlies olanzapine-induced weight gain","author":"Qian","year":"2023","journal-title":"Microbiology Spectrum"},{"key":"10.1016\/j.ejpb.2024.114453_b0095","article-title":"Olanzapine-induced lipid disturbances: A potential mechanism through the gut microbiota-brain axis","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114453_b0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2024.114453_b0105","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1208\/s12249-015-0449-z","article-title":"Design, optimization, and evaluation of lurasidone hydrochloride nanocrystals","volume":"17","author":"Shah","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114453_b0110","unstructured":"S.P. Inc, Latuda: Highlights of Prescribing Information, in, 2018."},{"key":"10.1016\/j.ejpb.2024.114453_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.ejpb.2024.114453_b0120","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia","volume":"63","author":"Perkins","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejpb.2024.114453_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121098","article-title":"Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone","volume":"608","author":"Meola","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114453_b0130","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3109\/03639045.2015.1118496","article-title":"Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state","volume":"42","author":"Miao","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2024.114453_b0135","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1080\/03639045.2019.1593434","article-title":"Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia","volume":"45","author":"Patel","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2024.114453_b0140","first-page":"283","article-title":"Solubility enhancement of lurasidone hydrochloride by preparing SMEDDS","volume":"7","author":"Jangipuria","year":"2015","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.ejpb.2024.114453_b0145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/01932691.2021.1984937","article-title":"Estimation of lurasidone hydrochloride equilibrium solubility in a polymeric solid dispersion using thermal analysis and thermodynamic modeling","volume":"44","author":"Barbari\u0107","year":"2023","journal-title":"J. Dispers. Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114453_b0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/bdd.2252","article-title":"Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder","volume":"41","author":"Pardhi","year":"2020","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2024.114453_b0155","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/acs.cgd.5b00349","article-title":"Coamorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior","volume":"15","author":"Qian","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2024.114453_b0160","first-page":"437","article-title":"The effect of drug ionization on lipid-based formulations for the oral delivery of anti-psychotics","volume":"8","author":"Meola","year":"2020","journal-title":"ADMET and DMPK"},{"key":"10.1016\/j.ejpb.2024.114453_b0165","doi-asserted-by":"crossref","first-page":"2403914","DOI":"10.1002\/adfm.202403914","article-title":"Inulin-lipid core-shell microcapsules target the gut microbiota and mimic the pharmaceutical food effect for improved oral antipsychotic delivery","author":"Meola","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2024.114453_b0170","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16507","article-title":"The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats","author":"Kamath","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114453_b0175","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat","volume":"158","author":"Eder","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejpb.2024.114453_b0180","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/cap.2012.0099","article-title":"Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia","volume":"23","author":"Kemp","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejpb.2024.114453_b0185","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/jcm8101605","article-title":"Analysis of gut microbiota and their metabolic potential in patients with schizophrenia treated with olanzapine: results from a six-week observational prospective cohort study","volume":"8","author":"Pe\u0142ka-Wysiecka","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2024.114453_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103307","article-title":"The gut microbiome influences the bioavailability of olanzapine in rats","volume":"66","author":"Cussotto","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejpb.2024.114453_b0195","article-title":"Psycho-pharmacomicrobiomics: a systematic review and meta-analysis","author":"Minichino","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejpb.2024.114453_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1757-4749-4-16","article-title":"Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes","volume":"4","author":"Saad","year":"2012","journal-title":"Gut Pathogens"},{"key":"10.1016\/j.ejpb.2024.114453_b0205","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00213-019-5185-8","article-title":"Psychotropics and the microbiome: a chamber of secrets","volume":"236","author":"Cussotto","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejpb.2024.114453_b0210","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114453_b0215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","article-title":"Physical chemistry of supersaturated solutions and implications for oral absorption","volume":"101","author":"Taylor","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114453_b0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2024.114453_b0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2018.03.018","article-title":"Synergistic effect of PLGA nanoparticles and submicron triglyceride droplets in enhancing the intestinal solubilisation of a lipophilic weak base","volume":"118","author":"Joyce","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114453_b0230","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.xphs.2018.09.016","article-title":"Improving Correlations Between Drug Solubilization and In Vitro Lipolysis by Monitoring the Phase Partitioning of Lipolytic Species for Lipid-Based Formulations","volume":"108","author":"Dening","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114453_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106556","article-title":"Lipid based formulations as supersaturating oral delivery systems: From current to future industrial applications","volume":"189","author":"Holm","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114453_b0240","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.3390\/ijerph17207618","article-title":"The gut microbiota and inflammation: an overview","volume":"17","author":"Al Bander","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ejpb.2024.114453_b0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12929-019-0554-5","article-title":"Current understanding of the gut microbiota shaping mechanisms","volume":"26","author":"Chang","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejpb.2024.114453_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110857","article-title":"Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota","volume":"133","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2024.114453_b0255","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3389\/fmicb.2018.02897","article-title":"Comparative microbiome signatures and short-chain fatty acids in mouse, rat, non-human primate, and human feces","volume":"9","author":"Nagpal","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2024.114453_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dmm.017400","article-title":"How informative is the mouse for human gut microbiota research?","volume":"8","author":"Nguyen","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejpb.2024.114453_b0265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-017-2693-8","article-title":"Mouse models for human intestinal microbiota research: a critical evaluation","volume":"75","author":"Hugenholtz","year":"2018","journal-title":"Cell. Mol. Life Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:19:47Z","timestamp":1730092787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124002790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"alternative-id":["S0939641124002790"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114453","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contrasting the pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114453"}}